Pharma Mar (PHM) Corporate presentation summary

Strategic vision and leadership

• Focused on marine-derived oncology drugs, aiming to remain a global leader in marine medicinal discovery and innovation.

• Fully integrated commercial-stage biotech with a diversified pipeline and established European sales force.

Product portfolio and pipeline

• Three approved oncology products: Yondelis, Aplidin, and Zepzelca, with Zepzelca as a standard of care in 2nd line SCLC in the US.

• Expanding pipeline includes late and early-stage assets, with ongoing trials in SCLC and leiomyosarcoma.

• PM54 and PM534 in Phase I, targeting solid tumors with novel mechanisms.

Clinical development and trial results

• IMforte Phase 3 trial showed statistically significant and clinically meaningful improvements in OS and PFS for lurbinectedin plus atezolizumab in first-line maintenance SCLC.

• Safety profile manageable, with most adverse events not leading to discontinuation.

• LAGOON Phase 3 trial in 2nd line SCLC completed recruitment; topline data expected in 2026.